Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Operating Margin (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Operating Margin for 12 consecutive years, with 33973.08% as the latest value for Q1 2026.

  • For Q1 2026, Operating Margin fell 3198317.0% year-over-year to 33973.08%; the TTM value through Mar 2026 reached 16088.59%, up 1624577.0%, while the annual FY2025 figure was 35851.25%, 3573656.0% down from the prior year.
  • Operating Margin hit 33973.08% in Q1 2026 for Cartesian Therapeutics, down from 5423.38% in the prior quarter.
  • Across five years, Operating Margin topped out at 5423.38% in Q4 2025 and bottomed at 33973.08% in Q1 2026.
  • Average Operating Margin over 5 years is 2456.89%, with a median of 214.0% recorded in 2024.
  • Year-over-year, Operating Margin soared 350992bps in 2025 and then plummeted -3198317bps in 2026.
  • Cartesian Therapeutics' Operating Margin stood at 50.59% in 2022, then tumbled by -769bps to 439.54% in 2023, then skyrocketed by 535bps to 1913.46% in 2024, then soared by 183bps to 5423.38% in 2025, then crashed by -726bps to 33973.08% in 2026.
  • According to Business Quant data, Operating Margin over the past three periods came in at 33973.08%, 5423.38%, and 4660.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.